Patients using the MGuard device exhibited significant improvement in micro-vascular criteria compared with those treated with bare metal stents.
Medical device company InspireMD Ltd. (Bulletin Board: NPSR), which develops proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, has reported positive clinical results from a trial conducted in Chile. The study showed that acute ST-elevation myocardial infarction patients who underwent coronary angioplasty with the company's MGuard device exhibited statistically significant improvement in micro-vascular criteria compared with those treated with traditional bare metal stents.
InspireMD presented the study in Washington, D.C., at the Cardiovascular Research Technologies conference. "Every perfusion parameter measured in our study displayed superior outcomes in the MGuard group compared to the BMS group," said lead researcher Dr. Dante Lindefjeld. "Additional randomized trials are now appropriate to gather more data about the role of MGuard in clinical use."
InspireMD CTO and VP R&D Eli Bar said, "The results of this 40-patient study add to the growing body of data about MGuard's efficacy."
Published by Globes, Israel business news - www.globes-online.com - on February 7, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012